| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Activated PI3K/AKT and MAPK pathways are potential good prognostic markers in node-positive, triple-negative breast cancer
|
Hashimoto, K.
|
|
|
25 |
10 |
p. 1973-1979
|
artikel
|
| 2 |
Adjuvant chemotherapy for bladder cancer—why does level 1 evidence not support it?
|
Raghavan, D.
|
|
|
25 |
10 |
p. 1930-1934
|
artikel
|
| 3 |
A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer †
|
McNeish, I.A.
|
|
|
25 |
10 |
p. 1988-1995
|
artikel
|
| 4 |
A simple technique to estimate best- and worst-case survival in patients with metastatic colorectal cancer treated with chemotherapy
|
Williams, M.
|
|
|
25 |
10 |
p. 2014-2019
|
artikel
|
| 5 |
Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer
|
Azuma, K.
|
|
|
25 |
10 |
p. 1935-1940
|
artikel
|
| 6 |
Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study
|
Fallah, M.
|
|
|
25 |
10 |
p. 2025-2030
|
artikel
|
| 7 |
Body mass index and survival in women with breast cancer—systematic literature review and meta-analysis of 82 follow-up studies
|
Chan, D.S.M.
|
|
|
25 |
10 |
p. 1901-1914
|
artikel
|
| 8 |
Chronic natural killer lymphoproliferative disorders: characteristics of an international cohort of 70 patients
|
Poullot, E.
|
|
|
25 |
10 |
p. 2030-2035
|
artikel
|
| 9 |
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC
|
Leduc, C.
|
|
|
25 |
10 |
p. 2092
|
artikel
|
| 10 |
Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer
|
Morris, V.K.
|
|
|
25 |
10 |
p. 2008-2014
|
artikel
|
| 11 |
Detection of circulating tumor cells for prediction of recurrence after adjuvant chemoradiation in locally advanced squamous cell carcinoma of the head and neck
|
Tinhofer, I.
|
|
|
25 |
10 |
p. 2042-2047
|
artikel
|
| 12 |
Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium
|
Bosetti, C.
|
|
|
25 |
10 |
p. 2065-2072
|
artikel
|
| 13 |
Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features
|
Missiaglia, E.
|
|
|
25 |
10 |
p. 1995-2001
|
artikel
|
| 14 |
Drug selection and dosing in pregnant cancer patients: insights from clinical pharmacokinetics
|
Berveiller, P.
|
|
|
25 |
10 |
p. 1869-1870
|
artikel
|
| 15 |
Editorial board
|
|
|
|
25 |
10 |
p. ii-iii
|
artikel
|
| 16 |
EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer
|
Heymach, J.V.
|
|
|
25 |
10 |
p. 1941-1948
|
artikel
|
| 17 |
Erlotinib treatment of meningeal carcinomatosis in lung cancer: more is better
|
Cessot, A.
|
|
|
25 |
10 |
p. 2093-2094
|
artikel
|
| 18 |
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) †
|
Cardoso, F.
|
|
|
25 |
10 |
p. 1871-1888
|
artikel
|
| 19 |
Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancer
|
Tannock, I.F.
|
|
|
25 |
10 |
p. 2096
|
artikel
|
| 20 |
Fourfold increased detection of Lynch syndrome by raising age limit for tumour genetic testing from 50 to 70 years is cost-effective
|
Sie, A.S.
|
|
|
25 |
10 |
p. 2001-2007
|
artikel
|
| 21 |
Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303)
|
Wanebo, H.J.
|
|
|
25 |
10 |
p. 2036-2041
|
artikel
|
| 22 |
Mutant allele frequency predicts the efficacy of EGFR-TKIs in lung adenocarcinoma harboring the L858R mutation
|
Ono, A.
|
|
|
25 |
10 |
p. 1948-1953
|
artikel
|
| 23 |
On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases
|
Gaudy-Marqueste, C.
|
|
|
25 |
10 |
p. 2086-2091
|
artikel
|
| 24 |
Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel
|
van Hasselt, J.G.C.
|
|
|
25 |
10 |
p. 2059-2065
|
artikel
|
| 25 |
Pancreatic cancer risk after treatment of Hodgkin lymphoma
|
Dores, G.M.
|
|
|
25 |
10 |
p. 2073-2079
|
artikel
|
| 26 |
Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study
|
Pivot, X.
|
|
|
25 |
10 |
p. 1979-1987
|
artikel
|
| 27 |
Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma
|
Foote, M.C.
|
|
|
25 |
10 |
p. 2047-2052
|
artikel
|
| 28 |
Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients
|
Collen, C.
|
|
|
25 |
10 |
p. 1954-1959
|
artikel
|
| 29 |
Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma
|
Inwards, D.J.
|
|
|
25 |
10 |
p. 2020-2024
|
artikel
|
| 30 |
Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer
|
Rothé, F.
|
|
|
25 |
10 |
p. 1959-1965
|
artikel
|
| 31 |
Prediction of treatment-related toxicity and outcome with geriatric assessment in elderly patients with solid malignancies treated with chemotherapy: a systematic review
|
Versteeg, K.S.
|
|
|
25 |
10 |
p. 1914-1918
|
artikel
|
| 32 |
Prevalence and correlates of unmet supportive care needs in patients with resected invasive cutaneous melanoma
|
Molassiotis, A.
|
|
|
25 |
10 |
p. 2052-2058
|
artikel
|
| 33 |
Prognostic information of a previously diagnosed sister is an independent prognosticator for a newly diagnosed sister with breast cancer
|
Lindström, L.S.
|
|
|
25 |
10 |
p. 1966-1972
|
artikel
|
| 34 |
Prognostic significance of miR-34a in Ewing sarcoma is associated with cyclin D1 and ki-67 expression
|
Marino, M.T.
|
|
|
25 |
10 |
p. 2080-2086
|
artikel
|
| 35 |
Reply to the letter to the editor ‘Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC’ by Ou et al.
|
Ou, S.-H.I.
|
|
|
25 |
10 |
p. 2093
|
artikel
|
| 36 |
Reply to the letter to the editor ‘Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancer’ Tannock and Pond
|
Rugo, H.S.
|
|
|
25 |
10 |
p. 2096-2098
|
artikel
|
| 37 |
Reply to the letter to the editor ‘Treating breast cancer with trabectedin: a new arsenal’ by L. Malik
|
Delaloge, S.
|
|
|
25 |
10 |
p. 2095
|
artikel
|
| 38 |
Table of Contents
|
|
|
|
25 |
10 |
p. iv-vi
|
artikel
|
| 39 |
The efficacy and safety of probiotics in people with cancer: a systematic review
|
Redman, M.G.
|
|
|
25 |
10 |
p. 1919-1929
|
artikel
|
| 40 |
The mutational spectrum of squamous-cell carcinoma of the head and neck: targetable genetic events and clinical impact
|
Mountzios, G.
|
|
|
25 |
10 |
p. 1889-1900
|
artikel
|
| 41 |
Treating breast cancer with trabectedin: a new arsenal
|
Malik, L.
|
|
|
25 |
10 |
p. 2094-2095
|
artikel
|
Tijdschrift beschrijving